Department of Neurosurgery, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.
Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland.
Acta Neurochir (Wien). 2022 Jul;164(7):1815-1826. doi: 10.1007/s00701-022-05250-6. Epub 2022 May 21.
Decompressive hemicraniectomy (DHC) is a potentially lifesaving procedure in refractory intracranial hypertension, which can prevent death from brainstem herniation but may cause survival in a disabled state. The spectrum of indications is expanding, and we present long-term results in a series of patients suffering from aneurysmal subarachnoid hemorrhage (SAH).
We performed a retrospective analysis of previously registered data including all patients treated for SAH between 2010 and 2018 in a single institution. Patients treated with decompressive hemicraniectomy due to refractory intracranial hypertension were identified. Clinical outcome was assessed by means of the Glasgow outcome scale after 12 months.
Of all 341 SAH cases, a total of 82 (24.0%) developed intracranial hypertension. Of those, 63 (18.5%) patients progressed into refractory ICP elevation and were treated with DHC. Younger age (OR 0.959, 95% CI 0.933 to 0.984; p = 0.002), anterior aneurysm location (OR 0.253, 95% CI 0.080 to 0.799; 0.019; p = 0.019), larger aneurysm size (OR 1.106, 95% CI 1.025 to 1.194; p = 0.010), and higher Hunt and Hess grading (OR 1.944, 95% CI 1.431 to 2.641; p < 0.001) were independently associated with the need for DHC. After 1 year, 10 (15.9%) patients after DHC were categorized as favorable outcome. Only younger age was independently associated with favorable outcome (OR 0.968 95% CI 0.951 to 0.986; p = 0.001).
Decompressive hemicraniectomy, though lifesaving, has only a limited probability of survival in a clinically favorable condition. We identified young age to be the sole independent predictor of favorable outcome after DHC in SAH.
去骨瓣减压术(DHC)是治疗难治性颅内高压的一种潜在救生术,可以防止脑干疝导致的死亡,但可能导致残疾状态下的存活。适应证范围正在扩大,我们报告了一系列因蛛网膜下腔出血(SAH)而接受 DHC 治疗的患者的长期结果。
我们对之前注册的数据进行了回顾性分析,包括 2010 年至 2018 年在一家机构治疗的所有 SAH 患者。确定了因难治性颅内高压接受 DHC 治疗的患者。通过 12 个月后的格拉斯哥预后量表评估临床预后。
在所有 341 例 SAH 病例中,共有 82 例(24.0%)出现颅内高压。其中,63 例(18.5%)患者进展为难治性颅内压升高,接受 DHC 治疗。年龄较小(OR 0.959,95%CI 0.933 至 0.984;p=0.002)、前交通动脉瘤部位(OR 0.253,95%CI 0.080 至 0.799;0.019;p=0.019)、较大的动脉瘤大小(OR 1.106,95%CI 1.025 至 1.194;p=0.010)和较高的 Hunt 和 Hess 分级(OR 1.944,95%CI 1.431 至 2.641;p<0.001)与 DHC 的需求独立相关。1 年后,82 例 DHC 后患者中有 10 例(15.9%)为预后良好。只有年龄较小与预后良好独立相关(OR 0.968,95%CI 0.951 至 0.986;p=0.001)。
去骨瓣减压术虽然可以救命,但只有有限的概率能在临床良好的情况下存活。我们发现年龄是 DHC 后 SAH 患者预后良好的唯一独立预测因素。